540 related articles for article (PubMed ID: 33509796)
1. Response to: 'Correspondence on 'Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries' by Nokhatha
Dejaco C; Bijlsma JW; Buttgereit F
Ann Rheum Dis; 2021 Oct; 80(10):e171. PubMed ID: 33509796
[No Abstract] [Full Text] [Related]
2. Correspondence on 'Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries'.
Al Nokhatha S; MacEoin N; Conway R
Ann Rheum Dis; 2021 Oct; 80(10):e170. PubMed ID: 33509797
[No Abstract] [Full Text] [Related]
3. Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado
Bourguiba R; Delplanque M; Savey L; Hentgen V; Grateau G; Georgin-Lavialle S;
Ann Rheum Dis; 2023 Dec; 82(12):e228. PubMed ID: 35817471
[No Abstract] [Full Text] [Related]
4. Exploring the role of rheumatic and musculoskeletal disease patient organisations during the COVID-19 pandemic: results from the REUMAVID study (phase 1).
Garrido-Cumbrera M; Marzo-Ortega H; Christen L; Correa-Fernández J; Sanz-Gómez S; Navarro-Compán V;
Clin Exp Rheumatol; 2022 May; 40(5):1062-1063. PubMed ID: 35084328
[No Abstract] [Full Text] [Related]
5. Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries.
Dejaco C; Alunno A; Bijlsma JW; Boonen A; Combe B; Finckh A; Machado PM; Padjen I; Sivera F; Stamm TA; Buttgereit F
Ann Rheum Dis; 2021 Apr; 80(4):518-526. PubMed ID: 33158877
[TBL] [Abstract][Full Text] [Related]
6. Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era.
Nikiphorou E; Alpizar-Rodriguez D; Gastelum-Strozzi A; Buch M; Peláez-Ballestas I
Rheumatology (Oxford); 2021 May; 60(5):2040-2045. PubMed ID: 33496334
[TBL] [Abstract][Full Text] [Related]
7. Response to: 'Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'' by Smerilli
Priori R; Pellegrino G; Colafrancesco S; Alessandri C; Ceccarelli F; Di Franco M; Riccieri V; Scrivo R; Sili Scavalli A; Spinelli FR; Conti F
Ann Rheum Dis; 2021 Oct; 80(10):e169. PubMed ID: 33962963
[No Abstract] [Full Text] [Related]
8. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.
Landewé RBM; Kroon FPB; Alunno A; Najm A; Bijlsma JW; Burmester GR; Caporali R; Combe B; Conway R; Curtis JR; Elkayam O; Gossec L; Heijstek MW; Haupt L; Iagnocco A; Isaacs JD; Juhász IÁ; Makri S; Mariette X; McInnes IB; Mehta P; Mueller-Ladner U; Schulze-Koops H; Smolen JS; Wiek D; Winthrop KL; Navarro-Compán V; Machado PM
Ann Rheum Dis; 2022 Dec; 81(12):1628-1639. PubMed ID: 35197264
[TBL] [Abstract][Full Text] [Related]
9. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis
Schulze-Koops H; Krueger K; Specker C
Ann Rheum Dis; 2021 Apr; 80(4):e61. PubMed ID: 32475833
[No Abstract] [Full Text] [Related]
10. Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'.
Smerilli G; Cipolletta E; Moscioni E; Francioso F; Risa AM; Maccarrone V; Zompa D; Di Matteo A; Di Carlo M; De Angelis R; Salaffi F; Filippucci E; Grassi W
Ann Rheum Dis; 2021 Oct; 80(10):e168. PubMed ID: 33962960
[No Abstract] [Full Text] [Related]
11. Impact of COVID-19 pandemic on management of autoimmune and inflammatory diseases in Morocco.
Wafa A; Hicham H; Hajar K; Mouna M; Zoubida MT; Mohamed A
Pan Afr Med J; 2020; 37():240. PubMed ID: 33552358
[No Abstract] [Full Text] [Related]
12. Biological therapies in children with rheumatic diseases during the COVID-19 pandemic: A single-centre experience.
Aydın F; Kurt T; Sezer M; Tekgöz N; Ekici Tekin Z; Kanık Yüksek S; Çelikel Acar B
Int J Clin Pract; 2021 Jul; 75(7):e14030. PubMed ID: 34233400
[No Abstract] [Full Text] [Related]
13. Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease.
Robinson PC; Kim AHJ
Best Pract Res Clin Rheumatol; 2021 Mar; 35(1):101664. PubMed ID: 33610466
[No Abstract] [Full Text] [Related]
14. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic.
Fragoulis GE; Evangelatos G; Arida A; Bournia VK; Fragiadaki K; Karamanakos A; Kravvariti E; Laskari K; Panopoulos S; Pappa M; Tektonidou MG; Sfikakis PP
Ann Rheum Dis; 2021 Apr; 80(4):e60. PubMed ID: 32475830
[No Abstract] [Full Text] [Related]
15. [SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments].
Leipe J; Hoyer BF; Iking-Konert C; Schulze-Koops H; Specker C; Krüger K
Z Rheumatol; 2020 Sep; 79(7):686-691. PubMed ID: 32845393
[TBL] [Abstract][Full Text] [Related]
16. The psychological impact of the COVID-19 pandemic on Dutch people with and without an inflammatory rheumatic disease.
Koppert TY; Jacobs JWG; Geenen R
Rheumatology (Oxford); 2021 Aug; 60(8):3709-3715. PubMed ID: 33313870
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations.
Grainger R; Kim AHJ; Conway R; Yazdany J; Robinson PC
Nat Rev Rheumatol; 2022 Apr; 18(4):191-204. PubMed ID: 35217850
[TBL] [Abstract][Full Text] [Related]
18. Implementation of podiatry telephone appointments for people with rheumatic and musculoskeletal diseases.
Palmer JL; Siddle HJ; Redmond AC; Alcacer-Pitarch B
J Foot Ankle Res; 2021 Jan; 14(1):4. PubMed ID: 33413562
[TBL] [Abstract][Full Text] [Related]
19. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
[TBL] [Abstract][Full Text] [Related]
20. Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry.
Glintborg B; Jensen DV; Engel S; Terslev L; Pfeiffer Jensen M; Hendricks O; Ostergaard M; Horskjær Rasmussen S; Adelsten T; Colic A; Danebod K; Kildemand M; Loft AG; Munk HL; Pedersen JK; Østgård RD; Møller Sørensen C; Krogh NS; Agerbo J; Ziegler C; Hetland M
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33402443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
